Cohen Ann 4

What Happened Ann Cohen, a director of Niagen Bioscience, was granted an award of 31,746 derivative securities on June 24, 2026. The Form 4 reports an acquisition at a $0 per-share price (total reported value $0). This is a compensation-style award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely).
• Amount: 31,746 derivative shares (reported at $0.00 per share; total $0).
• Vesting: Footnote states the option vests 100% on June 24, 2027.
• Shares owned after transaction: Not specified in the provided filing.
• Transaction type code: A = Award/Grant (derivative security).

Context

• This grant represents a future interest in equity (a derivative/option award) and does not represent immediate, free-trading shares until vesting/exercise conditions are met.
• Such awards are commonly part of director compensation; they are informational rather than a direct buy/sell signal.